Compare,PMID,Parameter,Sentece,Title,Type,URL,Units,Value,id,Drugbank_id,Name
,2597363,Concentration,Concentration of plasma AVP increased slightly from 3.8 +/- 1.5 pg/ml after induction and increased 3-fold after sternotomy.,Responses of vasopressin release in patients with cardiopulmonary bypass anesthetized with enflurane and morphine. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2597363/),[pg] / [ml],3.8,344,DB00228,Enflurane
,8678276,Peak serum IFCs,Peak serum IFCs were higher with sevoflurane (34.5 mumol/l) than with enflurane (19.4 mumol/l).,"[Serum fluoride concentrations and exocrine kidney function with sevoflurane and enflurane. An open, randomized, comparative phase III study of patients with healthy kidneys]. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8678276/),[μM] / [l],34.5,8706,DB00228,Enflurane
,8678276,Peak serum IFCs,Peak serum IFCs were higher with sevoflurane (34.5 mumol/l) than with enflurane (19.4 mumol/l).,"[Serum fluoride concentrations and exocrine kidney function with sevoflurane and enflurane. An open, randomized, comparative phase III study of patients with healthy kidneys]. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8678276/),[μM] / [l],19.4,8707,DB00228,Enflurane
,8678276,area under the curve (AUC),The area under the curve (AUC) was greater with sevoflurane (688 mumol/l.h) than with enflurane (591 mumol/l.h).,"[Serum fluoride concentrations and exocrine kidney function with sevoflurane and enflurane. An open, randomized, comparative phase III study of patients with healthy kidneys]. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8678276/),[μM] / [h·l],688,8708,DB00228,Enflurane
,8678276,area under the curve (AUC),The area under the curve (AUC) was greater with sevoflurane (688 mumol/l.h) than with enflurane (591 mumol/l.h).,"[Serum fluoride concentrations and exocrine kidney function with sevoflurane and enflurane. An open, randomized, comparative phase III study of patients with healthy kidneys]. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8678276/),[μM] / [h·l],591,8709,DB00228,Enflurane
,8678276,peak serum IFCs,In our study 1.69 MAC-h sevoflurane produced peak serum IFCs of 34.5 mumol/l.,"[Serum fluoride concentrations and exocrine kidney function with sevoflurane and enflurane. An open, randomized, comparative phase III study of patients with healthy kidneys]. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8678276/),[μM] / [l],34.5,8710,DB00228,Enflurane
,1504187,maximum quantity,The maximum quantity was 5.5 micrograms in the washed autologous red cell concentrate.,[The effect of blood conservation techniques on the plasma concentration and elimination of midazolam in patients undergoing hip joint surgery]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1504187/),μg,5.5,21271,DB00228,Enflurane
,2619028,peak plasma concentrations,Group 2: Rectal midazolam 0.35 mg/kg has a remarkably short onset of action with peak plasma concentrations (71 ng/ml) in the range of sedative levels in adults occurring in 7.5 min.,[Pharmacokinetic studies following intravenous and rectal administration of midazolam in children]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2619028/),[ng] / [ml],71,28058,DB00228,Enflurane
,2619028,peak levels,"Group 3 patients had peak levels of midazolam of 246 ng/ml after 12.5 min, falling to an average concentration of 120 ng/ml after 2 h.",[Pharmacokinetic studies following intravenous and rectal administration of midazolam in children]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2619028/),[ng] / [ml],246,28059,DB00228,Enflurane
,2619028,peak levels,"Group 3 patients had peak levels of midazolam of 246 ng/ml after 12.5 min, falling to an average concentration of 120 ng/ml after 2 h.",[Pharmacokinetic studies following intravenous and rectal administration of midazolam in children]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2619028/),ng,120,28060,DB00228,Enflurane
,2619028,bioavailability,"The bioavailability of rectal midazolam, comparing the area under the median curves, is 4.7% in group 2 and 16.1% in group 3.",[Pharmacokinetic studies following intravenous and rectal administration of midazolam in children]. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2619028/),%,4.7,28061,DB00228,Enflurane
,2619028,bioavailability,"The bioavailability of rectal midazolam, comparing the area under the median curves, is 4.7% in group 2 and 16.1% in group 3.",[Pharmacokinetic studies following intravenous and rectal administration of midazolam in children]. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2619028/),%,16.1,28062,DB00228,Enflurane
,9350366,plasma concentrations,"With sevoflurane, plasma concentrations of nicardipine, five minutes after administration, (39.8 +/- 3.5 ng.ml-1, mean +/- SEM) were higher (P < 0.05) than in the other two groups (28.3 +/- 2.9 ng.ml-1, 32.6 +/- 4.3 ng.ml-1, enflurane and isoflurane, respectively).","Interactions between nicardipine and enflurane, isoflurane, and sevoflurane. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9350366/),[ng] / [ml],39.8,32819,DB00228,Enflurane
,9350366,plasma concentrations,"With sevoflurane, plasma concentrations of nicardipine, five minutes after administration, (39.8 +/- 3.5 ng.ml-1, mean +/- SEM) were higher (P < 0.05) than in the other two groups (28.3 +/- 2.9 ng.ml-1, 32.6 +/- 4.3 ng.ml-1, enflurane and isoflurane, respectively).","Interactions between nicardipine and enflurane, isoflurane, and sevoflurane. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9350366/),[ng] / [ml],28.3,32820,DB00228,Enflurane
,9350366,plasma concentrations,"With sevoflurane, plasma concentrations of nicardipine, five minutes after administration, (39.8 +/- 3.5 ng.ml-1, mean +/- SEM) were higher (P < 0.05) than in the other two groups (28.3 +/- 2.9 ng.ml-1, 32.6 +/- 4.3 ng.ml-1, enflurane and isoflurane, respectively).","Interactions between nicardipine and enflurane, isoflurane, and sevoflurane. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9350366/),[ng] / [ml],32.6,32821,DB00228,Enflurane
,9350366,half-life,"With isoflurane, the approximated half-life of nicardipine (14 +/- 4 min) was shorter and clearance (2.1 +/- 0.3 l.min-1) more rapid.","Interactions between nicardipine and enflurane, isoflurane, and sevoflurane. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9350366/),min,14,32822,DB00228,Enflurane
,9350366,clearance,"With isoflurane, the approximated half-life of nicardipine (14 +/- 4 min) was shorter and clearance (2.1 +/- 0.3 l.min-1) more rapid.","Interactions between nicardipine and enflurane, isoflurane, and sevoflurane. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9350366/),[l] / [min],2.1,32823,DB00228,Enflurane
,3582376,T1/2 pi,"Derived pharmacokinetic parameters indicated a rapid distribution (T1/2 pi = 1.24 +/- 0.83 min, T1/2 alpha = 7.55 +/- 3.97 min), a short elimination half-life (T1/2 beta = 86.9 +/- 15.6 min), a volume of the central compartment twice as large in females (Vc = 0.557 +/- 0.237 l kg-1) as in males (Vc = 0.274 +/- 0.144 l kg-1), a small distribution volume at steady state (Vss = 2.52 +/- 0.66 l kg-1) and a high total plasma clearance (ClP = 1547 +/- 385 ml min-1).",Pharmacokinetics of intravenously administered meptazinol during general anaesthesia in man. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3582376/),min,1.24,34526,DB00228,Enflurane
,3582376,T1/2 alpha,"Derived pharmacokinetic parameters indicated a rapid distribution (T1/2 pi = 1.24 +/- 0.83 min, T1/2 alpha = 7.55 +/- 3.97 min), a short elimination half-life (T1/2 beta = 86.9 +/- 15.6 min), a volume of the central compartment twice as large in females (Vc = 0.557 +/- 0.237 l kg-1) as in males (Vc = 0.274 +/- 0.144 l kg-1), a small distribution volume at steady state (Vss = 2.52 +/- 0.66 l kg-1) and a high total plasma clearance (ClP = 1547 +/- 385 ml min-1).",Pharmacokinetics of intravenously administered meptazinol during general anaesthesia in man. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3582376/),min,7.55,34527,DB00228,Enflurane
,3582376,elimination half-life (T1/2 beta,"Derived pharmacokinetic parameters indicated a rapid distribution (T1/2 pi = 1.24 +/- 0.83 min, T1/2 alpha = 7.55 +/- 3.97 min), a short elimination half-life (T1/2 beta = 86.9 +/- 15.6 min), a volume of the central compartment twice as large in females (Vc = 0.557 +/- 0.237 l kg-1) as in males (Vc = 0.274 +/- 0.144 l kg-1), a small distribution volume at steady state (Vss = 2.52 +/- 0.66 l kg-1) and a high total plasma clearance (ClP = 1547 +/- 385 ml min-1).",Pharmacokinetics of intravenously administered meptazinol during general anaesthesia in man. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3582376/),min,86.9,34528,DB00228,Enflurane
,3582376,Vc,"Derived pharmacokinetic parameters indicated a rapid distribution (T1/2 pi = 1.24 +/- 0.83 min, T1/2 alpha = 7.55 +/- 3.97 min), a short elimination half-life (T1/2 beta = 86.9 +/- 15.6 min), a volume of the central compartment twice as large in females (Vc = 0.557 +/- 0.237 l kg-1) as in males (Vc = 0.274 +/- 0.144 l kg-1), a small distribution volume at steady state (Vss = 2.52 +/- 0.66 l kg-1) and a high total plasma clearance (ClP = 1547 +/- 385 ml min-1).",Pharmacokinetics of intravenously administered meptazinol during general anaesthesia in man. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3582376/),[l] / [kg],0.557,34529,DB00228,Enflurane
,3582376,Vc,"Derived pharmacokinetic parameters indicated a rapid distribution (T1/2 pi = 1.24 +/- 0.83 min, T1/2 alpha = 7.55 +/- 3.97 min), a short elimination half-life (T1/2 beta = 86.9 +/- 15.6 min), a volume of the central compartment twice as large in females (Vc = 0.557 +/- 0.237 l kg-1) as in males (Vc = 0.274 +/- 0.144 l kg-1), a small distribution volume at steady state (Vss = 2.52 +/- 0.66 l kg-1) and a high total plasma clearance (ClP = 1547 +/- 385 ml min-1).",Pharmacokinetics of intravenously administered meptazinol during general anaesthesia in man. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3582376/),[l] / [kg],0.274,34530,DB00228,Enflurane
,3582376,distribution volume at steady state (Vss,"Derived pharmacokinetic parameters indicated a rapid distribution (T1/2 pi = 1.24 +/- 0.83 min, T1/2 alpha = 7.55 +/- 3.97 min), a short elimination half-life (T1/2 beta = 86.9 +/- 15.6 min), a volume of the central compartment twice as large in females (Vc = 0.557 +/- 0.237 l kg-1) as in males (Vc = 0.274 +/- 0.144 l kg-1), a small distribution volume at steady state (Vss = 2.52 +/- 0.66 l kg-1) and a high total plasma clearance (ClP = 1547 +/- 385 ml min-1).",Pharmacokinetics of intravenously administered meptazinol during general anaesthesia in man. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3582376/),[l] / [kg],2.52,34531,DB00228,Enflurane
,3582376,total plasma clearance (ClP,"Derived pharmacokinetic parameters indicated a rapid distribution (T1/2 pi = 1.24 +/- 0.83 min, T1/2 alpha = 7.55 +/- 3.97 min), a short elimination half-life (T1/2 beta = 86.9 +/- 15.6 min), a volume of the central compartment twice as large in females (Vc = 0.557 +/- 0.237 l kg-1) as in males (Vc = 0.274 +/- 0.144 l kg-1), a small distribution volume at steady state (Vss = 2.52 +/- 0.66 l kg-1) and a high total plasma clearance (ClP = 1547 +/- 385 ml min-1).",Pharmacokinetics of intravenously administered meptazinol during general anaesthesia in man. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3582376/),[ml] / [min],1547,34532,DB00228,Enflurane
,3582376,k10,"The elimination rate microconstant in females (k10 = 0.0577 +/- 0.0337 min-1) was significantly lower than in males (k10 = 0.1093 +/- 0.0437 min-1 with a lower drug fraction in the central compartment in the post-distributive phase (Fc = males: 0.08 +/- 0.02, females 0.19 +/- 0.11).",Pharmacokinetics of intravenously administered meptazinol during general anaesthesia in man. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3582376/),1/[min],0.0577,34533,DB00228,Enflurane
,3582376,k10,"The elimination rate microconstant in females (k10 = 0.0577 +/- 0.0337 min-1) was significantly lower than in males (k10 = 0.1093 +/- 0.0437 min-1 with a lower drug fraction in the central compartment in the post-distributive phase (Fc = males: 0.08 +/- 0.02, females 0.19 +/- 0.11).",Pharmacokinetics of intravenously administered meptazinol during general anaesthesia in man. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3582376/),1/[min],0.1093,34534,DB00228,Enflurane
,3582376,Fc,"The elimination rate microconstant in females (k10 = 0.0577 +/- 0.0337 min-1) was significantly lower than in males (k10 = 0.1093 +/- 0.0437 min-1 with a lower drug fraction in the central compartment in the post-distributive phase (Fc = males: 0.08 +/- 0.02, females 0.19 +/- 0.11).",Pharmacokinetics of intravenously administered meptazinol during general anaesthesia in man. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3582376/),,0.08,34535,DB00228,Enflurane
,3582376,Fc,"The elimination rate microconstant in females (k10 = 0.0577 +/- 0.0337 min-1) was significantly lower than in males (k10 = 0.1093 +/- 0.0437 min-1 with a lower drug fraction in the central compartment in the post-distributive phase (Fc = males: 0.08 +/- 0.02, females 0.19 +/- 0.11).",Pharmacokinetics of intravenously administered meptazinol during general anaesthesia in man. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3582376/),,0.19,34536,DB00228,Enflurane
,2503375,clearance,"Values for pharmacokinetic parameters of alfentanil were as follows: clearance, 5.2 +/- 2.0 ml kg-1 min-1; volume of distribution, 0.63 +/- 0.20 1 kg-1; and elimination half-life, 96.9 +/- 52.5 min.",A comparison of enflurane with alfentanil anaesthesia for gynaecological surgery. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2503375/),[ml] / [kg·min],5.2,41034,DB00228,Enflurane
,2503375,volume of distribution,"Values for pharmacokinetic parameters of alfentanil were as follows: clearance, 5.2 +/- 2.0 ml kg-1 min-1; volume of distribution, 0.63 +/- 0.20 1 kg-1; and elimination half-life, 96.9 +/- 52.5 min.",A comparison of enflurane with alfentanil anaesthesia for gynaecological surgery. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2503375/),[1] / [kg],0.63,41035,DB00228,Enflurane
,2503375,elimination half-life,"Values for pharmacokinetic parameters of alfentanil were as follows: clearance, 5.2 +/- 2.0 ml kg-1 min-1; volume of distribution, 0.63 +/- 0.20 1 kg-1; and elimination half-life, 96.9 +/- 52.5 min.",A comparison of enflurane with alfentanil anaesthesia for gynaecological surgery. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2503375/),min,96.9,41036,DB00228,Enflurane
,3179149,elimination half-life,"During neuroleptanalgesia, droperidol kinetics were linear over the dose range tested: the overall mean elimination half-life was 127 min, Vdss 103 litre and the plasma clearance 732 ml min-1.",Pharmacokinetics of droperidol in surgical patients under different conditions of anaesthesia. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3179149/),min,127,42436,DB00228,Enflurane
,3179149,Vdss,"During neuroleptanalgesia, droperidol kinetics were linear over the dose range tested: the overall mean elimination half-life was 127 min, Vdss 103 litre and the plasma clearance 732 ml min-1.",Pharmacokinetics of droperidol in surgical patients under different conditions of anaesthesia. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3179149/),l,103,42437,DB00228,Enflurane
,3179149,plasma clearance,"During neuroleptanalgesia, droperidol kinetics were linear over the dose range tested: the overall mean elimination half-life was 127 min, Vdss 103 litre and the plasma clearance 732 ml min-1.",Pharmacokinetics of droperidol in surgical patients under different conditions of anaesthesia. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3179149/),[ml] / [min],732,42438,DB00228,Enflurane
,9422901,volume of the central compartment,"The mean volume of the central compartment and volume of distribution at steady state were 42.3 (SD 11.8) ml kg-1 and 168.4 (31.5) ml kg-1, respectively, in control patients, and significantly greater (55.2 (13.4) ml kg-1 and 225.9 (53.3) ml kg-1) in the haemodilution patients (P < 0.05).",Pharmacokinetics of vecuronium during acute isovolaemic haemodilution. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9422901/),[ml] / [kg],42.3,44250,DB00228,Enflurane
,9422901,volume of the central compartment,"The mean volume of the central compartment and volume of distribution at steady state were 42.3 (SD 11.8) ml kg-1 and 168.4 (31.5) ml kg-1, respectively, in control patients, and significantly greater (55.2 (13.4) ml kg-1 and 225.9 (53.3) ml kg-1) in the haemodilution patients (P < 0.05).",Pharmacokinetics of vecuronium during acute isovolaemic haemodilution. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9422901/),[ml] / [kg],55.2,44251,DB00228,Enflurane
,9422901,volume of distribution at steady state,"The mean volume of the central compartment and volume of distribution at steady state were 42.3 (SD 11.8) ml kg-1 and 168.4 (31.5) ml kg-1, respectively, in control patients, and significantly greater (55.2 (13.4) ml kg-1 and 225.9 (53.3) ml kg-1) in the haemodilution patients (P < 0.05).",Pharmacokinetics of vecuronium during acute isovolaemic haemodilution. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9422901/),[ml] / [kg],168.4,44252,DB00228,Enflurane
,9422901,volume of distribution at steady state,"The mean volume of the central compartment and volume of distribution at steady state were 42.3 (SD 11.8) ml kg-1 and 168.4 (31.5) ml kg-1, respectively, in control patients, and significantly greater (55.2 (13.4) ml kg-1 and 225.9 (53.3) ml kg-1) in the haemodilution patients (P < 0.05).",Pharmacokinetics of vecuronium during acute isovolaemic haemodilution. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9422901/),[ml] / [kg],225.9,44253,DB00228,Enflurane
,9422901,elimination half-life,The elimination half-life was 50.3 (11.5) min in control patients and significantly greater (68.2 (15.1) min) in the haemodilution patients (P < 0.05).,Pharmacokinetics of vecuronium during acute isovolaemic haemodilution. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9422901/),min,50.3,44254,DB00228,Enflurane
,9422901,elimination half-life,The elimination half-life was 50.3 (11.5) min in control patients and significantly greater (68.2 (15.1) min) in the haemodilution patients (P < 0.05).,Pharmacokinetics of vecuronium during acute isovolaemic haemodilution. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9422901/),min,68.2,44255,DB00228,Enflurane
,7220596,elimination half-lives,"In male rats the elimination half-lives from the atmosphere of the exposure system amounted to 0.76h for halothane, 6.84h for enflurane and 0.64h for methoxyflurane.","Effects of thyroid dysfunction on the metabolism of halothane, enflurane and methoxyflurane in rats. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7220596/),h,0.76,52559,DB00228,Enflurane
,7220596,elimination half-lives,"In male rats the elimination half-lives from the atmosphere of the exposure system amounted to 0.76h for halothane, 6.84h for enflurane and 0.64h for methoxyflurane.","Effects of thyroid dysfunction on the metabolism of halothane, enflurane and methoxyflurane in rats. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7220596/),h,6.84,52560,DB00228,Enflurane
,7220596,elimination half-lives,"In male rats the elimination half-lives from the atmosphere of the exposure system amounted to 0.76h for halothane, 6.84h for enflurane and 0.64h for methoxyflurane.","Effects of thyroid dysfunction on the metabolism of halothane, enflurane and methoxyflurane in rats. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7220596/),h,0.64,52561,DB00228,Enflurane
,2048708,elimination half-time (t beta 1/2),Midazolam elimination half-time (t beta 1/2) was significantly shorter in group II than in groups III and I (52 min vs 126 min and 139 min; p less than 0.05).,[The effect of a thigh tourniquet on the pharmacokinetics of midazolam]. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2048708/),min,52,52850,DB00228,Enflurane
,2048708,elimination half-time (t beta 1/2),Midazolam elimination half-time (t beta 1/2) was significantly shorter in group II than in groups III and I (52 min vs 126 min and 139 min; p less than 0.05).,[The effect of a thigh tourniquet on the pharmacokinetics of midazolam]. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2048708/),min,126,52851,DB00228,Enflurane
,2048708,elimination half-time (t beta 1/2),Midazolam elimination half-time (t beta 1/2) was significantly shorter in group II than in groups III and I (52 min vs 126 min and 139 min; p less than 0.05).,[The effect of a thigh tourniquet on the pharmacokinetics of midazolam]. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2048708/),min,139,52852,DB00228,Enflurane
,2048708,initial midazolam,The measured initial midazolam mean concentrations in group II were twice those in groups III and I (655 ng/ml vs 323 ng/ml and 332 ng/ml).,[The effect of a thigh tourniquet on the pharmacokinetics of midazolam]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2048708/),[ng] / [ml],655,52853,DB00228,Enflurane
,2048708,mean concentrations,The measured initial midazolam mean concentrations in group II were twice those in groups III and I (655 ng/ml vs 323 ng/ml and 332 ng/ml).,[The effect of a thigh tourniquet on the pharmacokinetics of midazolam]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2048708/),[ng] / [ml],655,52854,DB00228,Enflurane
,2048708,mean concentrations,The measured initial midazolam mean concentrations in group II were twice those in groups III and I (655 ng/ml vs 323 ng/ml and 332 ng/ml).,[The effect of a thigh tourniquet on the pharmacokinetics of midazolam]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2048708/),[ng] / [ml],323,52855,DB00228,Enflurane
,2048708,mean concentrations,The measured initial midazolam mean concentrations in group II were twice those in groups III and I (655 ng/ml vs 323 ng/ml and 332 ng/ml).,[The effect of a thigh tourniquet on the pharmacokinetics of midazolam]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2048708/),[ng] / [ml],332,52856,DB00228,Enflurane
,747695,alpha,"The distribution of thiopentone to the tissues was very rapid, the alpha and beta distribution half-lives averaging 2.5 min and 46.4 min respectively for the patient group and 2.8 min and 48.7 min for the control group.",Pharmacokinetics of thiopentone: effects of enflurane and nitrous oxide anaesthesia and surgery. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/747695/),min,2.5,74077,DB00228,Enflurane
,747695,alpha,"The distribution of thiopentone to the tissues was very rapid, the alpha and beta distribution half-lives averaging 2.5 min and 46.4 min respectively for the patient group and 2.8 min and 48.7 min for the control group.",Pharmacokinetics of thiopentone: effects of enflurane and nitrous oxide anaesthesia and surgery. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/747695/),min,2.8,74078,DB00228,Enflurane
,747695,beta distribution half-lives,"The distribution of thiopentone to the tissues was very rapid, the alpha and beta distribution half-lives averaging 2.5 min and 46.4 min respectively for the patient group and 2.8 min and 48.7 min for the control group.",Pharmacokinetics of thiopentone: effects of enflurane and nitrous oxide anaesthesia and surgery. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/747695/),min,46.4,74079,DB00228,Enflurane
,747695,beta distribution half-lives,"The distribution of thiopentone to the tissues was very rapid, the alpha and beta distribution half-lives averaging 2.5 min and 46.4 min respectively for the patient group and 2.8 min and 48.7 min for the control group.",Pharmacokinetics of thiopentone: effects of enflurane and nitrous oxide anaesthesia and surgery. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/747695/),min,48.7,74080,DB00228,Enflurane
,747695,elimination half-life,The mean elimination half-life was 5.1 h for the patients and 5.7 h for the volunteers.,Pharmacokinetics of thiopentone: effects of enflurane and nitrous oxide anaesthesia and surgery. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/747695/),h,5.1,74081,DB00228,Enflurane
,747695,elimination half-life,The mean elimination half-life was 5.1 h for the patients and 5.7 h for the volunteers.,Pharmacokinetics of thiopentone: effects of enflurane and nitrous oxide anaesthesia and surgery. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/747695/),h,5.7,74082,DB00228,Enflurane
,760597,t1/2,"However, the terminal elimination phase was prolonged (t1/2 = 199 +/- 17 min).",Pharmacokinetics of 3H-fentanyl in the dog anesthetized with enflurane. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/760597/),min,199,82872,DB00228,Enflurane
,760597,apparent volume of distribution,The apparent volume of distribution was large (9.81/kg) and independent of dose.,Pharmacokinetics of 3H-fentanyl in the dog anesthetized with enflurane. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/760597/),1/[kg],9.81,82873,DB00228,Enflurane
,3221325,stable [MID],"Based on the pharmacokinetic parameters determined for Group 1, dogs in Group 2 (n = 4) received Mid as a continuous infusion of 21 micrograms kg-1 min-1 for 5 hr accompanied by an initial loading dose (3 mg/kg infused over 20 min) designed to produce a stable [MID] of 1000 ng/ml in plasma.",Pharmacokinetics and pharmacodynamics of midazolam in the enflurane-anesthetized dog. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3221325/),[ng] / [ml],1000,103116,DB00228,Enflurane
,3221325,"t1/2,z","Group 2: t1/2,z = 98 +/- 5 vs. 95 +/- 10 min (mean +/- SEM); V = 3.94 +/- 0.27 vs.",Pharmacokinetics and pharmacodynamics of midazolam in the enflurane-anesthetized dog. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3221325/),min,98,103117,DB00228,Enflurane
,3221325,"t1/2,z","Group 2: t1/2,z = 98 +/- 5 vs. 95 +/- 10 min (mean +/- SEM); V = 3.94 +/- 0.27 vs.",Pharmacokinetics and pharmacodynamics of midazolam in the enflurane-anesthetized dog. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3221325/),min,95,103118,DB00228,Enflurane
,3221325,V,"Group 2: t1/2,z = 98 +/- 5 vs. 95 +/- 10 min (mean +/- SEM); V = 3.94 +/- 0.27 vs.",Pharmacokinetics and pharmacodynamics of midazolam in the enflurane-anesthetized dog. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3221325/),,3.94,103119,DB00228,Enflurane
,3221325,Cl,2.98 +/- 25 L/kg; Cl = 28.5 +/- 3.1 vs.,Pharmacokinetics and pharmacodynamics of midazolam in the enflurane-anesthetized dog. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3221325/),,28.5,103120,DB00228,Enflurane
,3221325,[MID],"When administered as a continuous intravenous infusion (Group 2), [MID] remained stable at 949 +/- 53 ng/ml for more than 5 hr.",Pharmacokinetics and pharmacodynamics of midazolam in the enflurane-anesthetized dog. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3221325/),[ng] / [ml],949,103121,DB00228,Enflurane
,2709609,lung uptake,"After general anesthesia with thiamylal, enflurane, nitrous oxide and oxygen, the lung uptake was 30 approximately 40% following initial and additional administrations.",[Pharmacokinetics and the lung uptake of lidocaine during epidural anesthesia]. ,Uptake Volume-Q9,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2709609/),%,40,110647,DB00228,Enflurane
,7469101,elimination half-time (t1/2 beta),Morphine disposition was independent of dose in this fourfold range and was best described by a three-compartment model with a mean elimination half-time (t1/2 beta) of 104 +/- 5 min.,Pharmacokinetics of intravenous morphine in patients anesthetized with enflurane-nitrous oxide. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7469101/),min,104,120994,DB00228,Enflurane
,7469101,apparent volumes of distribution (Vd),"The apparent volumes of distribution (Vd) and of the central compartment (V1) were 3.4 +/- 0.2 and 0.13 +/- 0.02 l/kg, respectively, while the clearance (ClB) was 23 +/- 1 ml x min-1 x kg-1.",Pharmacokinetics of intravenous morphine in patients anesthetized with enflurane-nitrous oxide. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7469101/),[l] / [kg],3.4,120995,DB00228,Enflurane
,7469101,central compartment (V1),"The apparent volumes of distribution (Vd) and of the central compartment (V1) were 3.4 +/- 0.2 and 0.13 +/- 0.02 l/kg, respectively, while the clearance (ClB) was 23 +/- 1 ml x min-1 x kg-1.",Pharmacokinetics of intravenous morphine in patients anesthetized with enflurane-nitrous oxide. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7469101/),[l] / [kg],0.13,120996,DB00228,Enflurane
,7469101,clearance (ClB),"The apparent volumes of distribution (Vd) and of the central compartment (V1) were 3.4 +/- 0.2 and 0.13 +/- 0.02 l/kg, respectively, while the clearance (ClB) was 23 +/- 1 ml x min-1 x kg-1.",Pharmacokinetics of intravenous morphine in patients anesthetized with enflurane-nitrous oxide. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7469101/),[ml] / [kg·min],23,120997,DB00228,Enflurane
,7469101,t1/2 beta,Conjugated morphine was eliminated from plasma with a t1/2 beta of 169 +/- 15 min.,Pharmacokinetics of intravenous morphine in patients anesthetized with enflurane-nitrous oxide. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7469101/),min,169,120998,DB00228,Enflurane
,9620528,end,General anesthesia was induced with thiopental 4-6 mg/kg and fentanyl 2-4 microg/kg and was maintained with 60% nitrous oxide in oxygen and an end-tidal concentration of 1.5%-2% enflurane.,The pharmacokinetics of vecuronium in male and female patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9620528/),,1,134931,DB00228,Enflurane
,9620528,volume of the central compartment,"The volume of the central compartment and the volume of distribution at steady state were 39.6 +/- 8.6 and 164.8 +/- 29.3 mL/kg, respectively, in women.",The pharmacokinetics of vecuronium in male and female patients. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9620528/),[ml] / [kg],39.6,134932,DB00228,Enflurane
,9620528,volume of distribution at steady state,"The volume of the central compartment and the volume of distribution at steady state were 39.6 +/- 8.6 and 164.8 +/- 29.3 mL/kg, respectively, in women.",The pharmacokinetics of vecuronium in male and female patients. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9620528/),[ml] / [kg],164.8,134933,DB00228,Enflurane
,2889403,initial rate,"Thirty healthy surgical patients were given an initial 0.1 mg/kg bolus of vecuronium, followed by an infusion of vecuronium at an initial rate of 1.0 microgram .",Continuous infusion of vecuronium: the effect of anesthetic agents. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2889403/),,1,138618,DB00228,Enflurane
,2889403,infusion rates,"Vecuronium infusion rates (mean +/- SD) were similar for patients given enflurane (0.28 +/- 0.13 microgram . kg-1 . min-1) and isoflurane (0.30 +/- 0.13 microgram . kg-1 . min-1), but significantly higher in patients given fentanyl (0.92 +/- 0.37 microgram . kg-1 . min-1).",Continuous infusion of vecuronium: the effect of anesthetic agents. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2889403/),[μg] / [kg·min],0.28,138619,DB00228,Enflurane
,2889403,infusion rates,"Vecuronium infusion rates (mean +/- SD) were similar for patients given enflurane (0.28 +/- 0.13 microgram . kg-1 . min-1) and isoflurane (0.30 +/- 0.13 microgram . kg-1 . min-1), but significantly higher in patients given fentanyl (0.92 +/- 0.37 microgram . kg-1 . min-1).",Continuous infusion of vecuronium: the effect of anesthetic agents. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2889403/),[μg] / [kg·min],0.30,138620,DB00228,Enflurane
,2889403,infusion rates,"Vecuronium infusion rates (mean +/- SD) were similar for patients given enflurane (0.28 +/- 0.13 microgram . kg-1 . min-1) and isoflurane (0.30 +/- 0.13 microgram . kg-1 . min-1), but significantly higher in patients given fentanyl (0.92 +/- 0.37 microgram . kg-1 . min-1).",Continuous infusion of vecuronium: the effect of anesthetic agents. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2889403/),[μg] / [kg·min],0.92,138621,DB00228,Enflurane
,2889403,Css90,"Values for Css90 in the patients receiving enflurane and isoflurane were similar (71 +/- 34 and 72 +/- 44 ng/ml, respectively), but significantly higher in those receiving fentanyl (165 +/- 48 ng/ml).",Continuous infusion of vecuronium: the effect of anesthetic agents. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2889403/),[ng] / [ml],71,138622,DB00228,Enflurane
,2889403,Css90,"Values for Css90 in the patients receiving enflurane and isoflurane were similar (71 +/- 34 and 72 +/- 44 ng/ml, respectively), but significantly higher in those receiving fentanyl (165 +/- 48 ng/ml).",Continuous infusion of vecuronium: the effect of anesthetic agents. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2889403/),[ng] / [ml],72,138623,DB00228,Enflurane
,2889403,Css90,"Values for Css90 in the patients receiving enflurane and isoflurane were similar (71 +/- 34 and 72 +/- 44 ng/ml, respectively), but significantly higher in those receiving fentanyl (165 +/- 48 ng/ml).",Continuous infusion of vecuronium: the effect of anesthetic agents. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2889403/),[ng] / [ml],165,138624,DB00228,Enflurane
,2889403,Total plasma clearance,"Total plasma clearance was similar during enflurane, isoflurane, and fentanyl anesthesia (4.4 +/- 2.6, 4.6 +/- 1.2, and 5.6 +/- 1.9 ml X kg-1 min-1, respectively).",Continuous infusion of vecuronium: the effect of anesthetic agents. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2889403/),[ml] / [kg·min],4.4,138625,DB00228,Enflurane
,2889403,Total plasma clearance,"Total plasma clearance was similar during enflurane, isoflurane, and fentanyl anesthesia (4.4 +/- 2.6, 4.6 +/- 1.2, and 5.6 +/- 1.9 ml X kg-1 min-1, respectively).",Continuous infusion of vecuronium: the effect of anesthetic agents. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2889403/),[ml] / [kg·min],4.6,138626,DB00228,Enflurane
,2889403,Total plasma clearance,"Total plasma clearance was similar during enflurane, isoflurane, and fentanyl anesthesia (4.4 +/- 2.6, 4.6 +/- 1.2, and 5.6 +/- 1.9 ml X kg-1 min-1, respectively).",Continuous infusion of vecuronium: the effect of anesthetic agents. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2889403/),[ml] / [kg·min],5.6,138627,DB00228,Enflurane
,2897149,Vc,Pharmacokinetic analysis showed Vc 82 (+/- S.D. 26) ml/kg; VDSS 277 (+/- S.D. 71) ml/kg; clearance 2.01 (+/- S.D. 0.64) ml/kg/min; t1/2 beta 117 (+/- S.D. 24) min.,The pharmacokinetics and clinical effects of a low dose of alfentanil in elderly patients. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2897149/),[ml] / [kg],82,139625,DB00228,Enflurane
,2897149,VDSS,Pharmacokinetic analysis showed Vc 82 (+/- S.D. 26) ml/kg; VDSS 277 (+/- S.D. 71) ml/kg; clearance 2.01 (+/- S.D. 0.64) ml/kg/min; t1/2 beta 117 (+/- S.D. 24) min.,The pharmacokinetics and clinical effects of a low dose of alfentanil in elderly patients. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2897149/),[ml] / [kg],277,139626,DB00228,Enflurane
,2897149,clearance,Pharmacokinetic analysis showed Vc 82 (+/- S.D. 26) ml/kg; VDSS 277 (+/- S.D. 71) ml/kg; clearance 2.01 (+/- S.D. 0.64) ml/kg/min; t1/2 beta 117 (+/- S.D. 24) min.,The pharmacokinetics and clinical effects of a low dose of alfentanil in elderly patients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2897149/),[ml] / [kg·min],2.01,139627,DB00228,Enflurane
,2897149,t1/2 beta,Pharmacokinetic analysis showed Vc 82 (+/- S.D. 26) ml/kg; VDSS 277 (+/- S.D. 71) ml/kg; clearance 2.01 (+/- S.D. 0.64) ml/kg/min; t1/2 beta 117 (+/- S.D. 24) min.,The pharmacokinetics and clinical effects of a low dose of alfentanil in elderly patients. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2897149/),min,117,139628,DB00228,Enflurane
,2897149,minute volume,The clinical results showed a decrease in minute volume from a mean value of 5944 ml before alfentanil to 1240 ml 1 minute after alfentanil (P less than 0.001).,The pharmacokinetics and clinical effects of a low dose of alfentanil in elderly patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2897149/),ml,5944,139629,DB00228,Enflurane
,2897149,minute volume,The clinical results showed a decrease in minute volume from a mean value of 5944 ml before alfentanil to 1240 ml 1 minute after alfentanil (P less than 0.001).,The pharmacokinetics and clinical effects of a low dose of alfentanil in elderly patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2897149/),ml,1240,139630,DB00228,Enflurane
,15650985,t(1/2),The median t(1/2) of oxycodone varied from 5.1 to 5.9 hours.,Pharmacodynamics and pharmacokinetics of high-dose oxycodone infusion during and after coronary artery bypass grafting. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15650985/),h,5.1 to 5.9,144396,DB00228,Enflurane
,15650985,times to awakening,"The mean times to awakening were 3.8 hours and 7.0 hours in the groups OX 0.5 and 1.0, respectively.",Pharmacodynamics and pharmacokinetics of high-dose oxycodone infusion during and after coronary artery bypass grafting. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15650985/),h,3.8,144397,DB00228,Enflurane
,15650985,times to awakening,"The mean times to awakening were 3.8 hours and 7.0 hours in the groups OX 0.5 and 1.0, respectively.",Pharmacodynamics and pharmacokinetics of high-dose oxycodone infusion during and after coronary artery bypass grafting. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15650985/),h,7.0,144398,DB00228,Enflurane
,2573716,binding to,"Alfentanil binding to plasma proteins was 87.6% (s.d. 2.0) in the patients with chronic renal failure, and 89.7% (1.2) in patients with normal renal function (P = 0.025).",Disposition of alfentanil in patients receiving a renal transplant. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2573716/),%,87.6,165750,DB00228,Enflurane
,2573716,binding to,"Alfentanil binding to plasma proteins was 87.6% (s.d. 2.0) in the patients with chronic renal failure, and 89.7% (1.2) in patients with normal renal function (P = 0.025).",Disposition of alfentanil in patients receiving a renal transplant. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2573716/),%,89.7,165751,DB00228,Enflurane
,2573716,Elimination half life,"Elimination half life, mean residence time and apparent volume of distribution at steady state were not different in the two groups of patients (mean values: 142.4 and 120.2 min; 128.5 and 136.0 min; and 40.5 and 27.6 L, respectively in chronic renal failure patients and patients with normal renal function).",Disposition of alfentanil in patients receiving a renal transplant. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2573716/),min,142.4,165752,DB00228,Enflurane
,2573716,mean residence time,"Elimination half life, mean residence time and apparent volume of distribution at steady state were not different in the two groups of patients (mean values: 142.4 and 120.2 min; 128.5 and 136.0 min; and 40.5 and 27.6 L, respectively in chronic renal failure patients and patients with normal renal function).",Disposition of alfentanil in patients receiving a renal transplant. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2573716/),min,120.2,165753,DB00228,Enflurane
,2573716,mean residence time,"Elimination half life, mean residence time and apparent volume of distribution at steady state were not different in the two groups of patients (mean values: 142.4 and 120.2 min; 128.5 and 136.0 min; and 40.5 and 27.6 L, respectively in chronic renal failure patients and patients with normal renal function).",Disposition of alfentanil in patients receiving a renal transplant. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2573716/),min,128.5,165754,DB00228,Enflurane
,2573716,mean residence time,"Elimination half life, mean residence time and apparent volume of distribution at steady state were not different in the two groups of patients (mean values: 142.4 and 120.2 min; 128.5 and 136.0 min; and 40.5 and 27.6 L, respectively in chronic renal failure patients and patients with normal renal function).",Disposition of alfentanil in patients receiving a renal transplant. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2573716/),min,136.0,165755,DB00228,Enflurane
,2573716,apparent volume of distribution at steady state,"Elimination half life, mean residence time and apparent volume of distribution at steady state were not different in the two groups of patients (mean values: 142.4 and 120.2 min; 128.5 and 136.0 min; and 40.5 and 27.6 L, respectively in chronic renal failure patients and patients with normal renal function).",Disposition of alfentanil in patients receiving a renal transplant. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2573716/),l,40.5,165756,DB00228,Enflurane
,2573716,apparent volume of distribution at steady state,"Elimination half life, mean residence time and apparent volume of distribution at steady state were not different in the two groups of patients (mean values: 142.4 and 120.2 min; 128.5 and 136.0 min; and 40.5 and 27.6 L, respectively in chronic renal failure patients and patients with normal renal function).",Disposition of alfentanil in patients receiving a renal transplant. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2573716/),l,27.6,165757,DB00228,Enflurane
,2573716,Total drug clearance,Total drug clearance and Vd area were significantly increased in the chronic renal failure patients: 341.9 vs 211.8 mL min-1; and 69.3 and 35.5 L.,Disposition of alfentanil in patients receiving a renal transplant. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2573716/),[ml] / [min],341.9,165758,DB00228,Enflurane
,2573716,Total drug clearance,Total drug clearance and Vd area were significantly increased in the chronic renal failure patients: 341.9 vs 211.8 mL min-1; and 69.3 and 35.5 L.,Disposition of alfentanil in patients receiving a renal transplant. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2573716/),[ml] / [min],211.8,165759,DB00228,Enflurane
,2573716,Vd area,Total drug clearance and Vd area were significantly increased in the chronic renal failure patients: 341.9 vs 211.8 mL min-1; and 69.3 and 35.5 L.,Disposition of alfentanil in patients receiving a renal transplant. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2573716/),l,69.3,165760,DB00228,Enflurane
,2573716,Vd area,Total drug clearance and Vd area were significantly increased in the chronic renal failure patients: 341.9 vs 211.8 mL min-1; and 69.3 and 35.5 L.,Disposition of alfentanil in patients receiving a renal transplant. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2573716/),l,35.5,165761,DB00228,Enflurane
,1928855,central compartment volume,"The AIH only altered the central compartment volume (65.5 +/- 15.6 l in the control group vs 83.6 +/- 13.3 l in group II, p less than 0.01).",[Pharmacokinetics of propofol injected after deliberate preoperative hemodilution]. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1928855/),l,65.5,171206,DB00228,Enflurane
,1928855,central compartment volume,"The AIH only altered the central compartment volume (65.5 +/- 15.6 l in the control group vs 83.6 +/- 13.3 l in group II, p less than 0.01).",[Pharmacokinetics of propofol injected after deliberate preoperative hemodilution]. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1928855/),l,83.6,171207,DB00228,Enflurane
,1928855,Initial concentrations,"Initial concentrations were not significantly different in the two groups (2,892 +/- 762 ng.ml-1 in controls vs 2,373 +/- 589 ng.ml-1 in the others).",[Pharmacokinetics of propofol injected after deliberate preoperative hemodilution]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1928855/),[ng] / [ml],"2,892",171208,DB00228,Enflurane
,1928855,Initial concentrations,"Initial concentrations were not significantly different in the two groups (2,892 +/- 762 ng.ml-1 in controls vs 2,373 +/- 589 ng.ml-1 in the others).",[Pharmacokinetics of propofol injected after deliberate preoperative hemodilution]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1928855/),[ng] / [ml],"2,373",171209,DB00228,Enflurane
,11038831,fraction (Fd),"After induction of anesthesia and endotracheal intubation, desired fraction (Fd) of desflurane(6%), sevoflurane(2%), isoflurane (1.15%) and enflurane(1.7%) in oxygen and nitrous oxide(1:2) were inhaled in D, S, I and E groups, respectively.","[The pharmacokinetic study of desflurane, sevoflurane, isoflurane and enflurane in general anesthesia]. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11038831/),%,6,171264,DB00228,Enflurane
,11038831,fraction (Fd),"After induction of anesthesia and endotracheal intubation, desired fraction (Fd) of desflurane(6%), sevoflurane(2%), isoflurane (1.15%) and enflurane(1.7%) in oxygen and nitrous oxide(1:2) were inhaled in D, S, I and E groups, respectively.","[The pharmacokinetic study of desflurane, sevoflurane, isoflurane and enflurane in general anesthesia]. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11038831/),%,2,171265,DB00228,Enflurane
,11038831,fraction (Fd),"After induction of anesthesia and endotracheal intubation, desired fraction (Fd) of desflurane(6%), sevoflurane(2%), isoflurane (1.15%) and enflurane(1.7%) in oxygen and nitrous oxide(1:2) were inhaled in D, S, I and E groups, respectively.","[The pharmacokinetic study of desflurane, sevoflurane, isoflurane and enflurane in general anesthesia]. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11038831/),%,1.15,171266,DB00228,Enflurane
,11038831,fraction (Fd),"After induction of anesthesia and endotracheal intubation, desired fraction (Fd) of desflurane(6%), sevoflurane(2%), isoflurane (1.15%) and enflurane(1.7%) in oxygen and nitrous oxide(1:2) were inhaled in D, S, I and E groups, respectively.","[The pharmacokinetic study of desflurane, sevoflurane, isoflurane and enflurane in general anesthesia]. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11038831/),%,1.7,171267,DB00228,Enflurane
,11038831,fractional end tidal alveolar concentration (Fa),The fractional end tidal alveolar concentration (Fa) was adjusted to 1MAC during the maintenance of anesthsia.,"[The pharmacokinetic study of desflurane, sevoflurane, isoflurane and enflurane in general anesthesia]. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11038831/),,1,171268,DB00228,Enflurane
,7428802,apparent plasma half-life,Pharmacokinetic analysis of the net plasma F concentrations showed that the apparent plasma half-life of F was longer when urine was acid (4.3 +/- 0.6h: SD; n = 5) than when it was alkaline (2.4 +/- 0.4h).,Fluoride pharmacokinetics during acid-base balance changes in man. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7428802/),h,4.3,173556,DB00228,Enflurane
,7428802,apparent plasma half-life,Pharmacokinetic analysis of the net plasma F concentrations showed that the apparent plasma half-life of F was longer when urine was acid (4.3 +/- 0.6h: SD; n = 5) than when it was alkaline (2.4 +/- 0.4h).,Fluoride pharmacokinetics during acid-base balance changes in man. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7428802/),h,2.4,173557,DB00228,Enflurane
,7428802,renal clearance,"This could be explained by changes in the renal clearance of F, which was always lower with an acid (61.5 +/- 8.1 ml/min) than an alkaline (97.8 +/- 10.4 ml/min) urine.",Fluoride pharmacokinetics during acid-base balance changes in man. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7428802/),[ml] / [min],61.5,173558,DB00228,Enflurane
,7428802,renal clearance,"This could be explained by changes in the renal clearance of F, which was always lower with an acid (61.5 +/- 8.1 ml/min) than an alkaline (97.8 +/- 10.4 ml/min) urine.",Fluoride pharmacokinetics during acid-base balance changes in man. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7428802/),[ml] / [min],97.8,173559,DB00228,Enflurane
,7428802,apparent extra-renal clearance,"The apparent extra-renal clearance, which mainly represents clearance to the bone-pool, was also significantly higher during production of alkaline (109.2 +/- 20.2 ml/min) than of acid (86.3 +/- 21.3 ml/min) urine.",Fluoride pharmacokinetics during acid-base balance changes in man. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7428802/),[ml] / [min],109.2,173560,DB00228,Enflurane
,7428802,apparent extra-renal clearance,"The apparent extra-renal clearance, which mainly represents clearance to the bone-pool, was also significantly higher during production of alkaline (109.2 +/- 20.2 ml/min) than of acid (86.3 +/- 21.3 ml/min) urine.",Fluoride pharmacokinetics during acid-base balance changes in man. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7428802/),[ml] / [min],86.3,173561,DB00228,Enflurane
,1622764,half-life,"In the liver of thiobarbitone-anaesthetized rats the half-life for enflurane following exposure to 0.15% (v/v) for 30 min was 76 min but this could be decreased to 39 min by pretreatment of the animals with isoniazid (0.1% in the drinking water for 7 days), an agent known to enhance enflurane metabolism.",19F NMR studies of enflurane elimination and metabolism. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1622764/),min,76,189292,DB00228,Enflurane
,1622764,half-life,"In the liver of thiobarbitone-anaesthetized rats the half-life for enflurane following exposure to 0.15% (v/v) for 30 min was 76 min but this could be decreased to 39 min by pretreatment of the animals with isoniazid (0.1% in the drinking water for 7 days), an agent known to enhance enflurane metabolism.",19F NMR studies of enflurane elimination and metabolism. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1622764/),min,39,189293,DB00228,Enflurane
,2960465,central compartment concentration,"At that point, an infusion of sufentanil, aimed to reach a central compartment concentration of 5 ng.",Sufentanil disposition during cardiopulmonary bypass. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2960465/),ng,5,190294,DB00228,Enflurane
,2960465,Plasma concentrations,Plasma concentrations of sufentanil reached 3.8 +/- 0.4 ng.,Sufentanil disposition during cardiopulmonary bypass. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2960465/),ng,3.8,190295,DB00228,Enflurane
,6650910,terminal elimination half-time (t 1/2 beta,"The terminal elimination half-time (t 1/2 beta = 211 min), the apparent volume of distribution (9.5 l X kg-1), the volume of the central compartment (1.14 l X kg-1), and the clearance (37 ml X kg-1 X min-1) of fentanyl were independent of dose over the 6.4-640 micrograms X kg-1 dose range.",Dose-independent pharmacokinetics of fentanyl. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6650910/),min,211,192168,DB00228,Enflurane
,6650910,apparent volume of distribution,"The terminal elimination half-time (t 1/2 beta = 211 min), the apparent volume of distribution (9.5 l X kg-1), the volume of the central compartment (1.14 l X kg-1), and the clearance (37 ml X kg-1 X min-1) of fentanyl were independent of dose over the 6.4-640 micrograms X kg-1 dose range.",Dose-independent pharmacokinetics of fentanyl. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6650910/),[l] / [kg],9.5,192169,DB00228,Enflurane
,6650910,volume of the central compartment,"The terminal elimination half-time (t 1/2 beta = 211 min), the apparent volume of distribution (9.5 l X kg-1), the volume of the central compartment (1.14 l X kg-1), and the clearance (37 ml X kg-1 X min-1) of fentanyl were independent of dose over the 6.4-640 micrograms X kg-1 dose range.",Dose-independent pharmacokinetics of fentanyl. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6650910/),[l] / [kg],1.14,192170,DB00228,Enflurane
,6650910,clearance,"The terminal elimination half-time (t 1/2 beta = 211 min), the apparent volume of distribution (9.5 l X kg-1), the volume of the central compartment (1.14 l X kg-1), and the clearance (37 ml X kg-1 X min-1) of fentanyl were independent of dose over the 6.4-640 micrograms X kg-1 dose range.",Dose-independent pharmacokinetics of fentanyl. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6650910/),[ml] / [kg·min],37,192171,DB00228,Enflurane
,2888422,plasma concentrations,"In a first group of seven dogs, studied awake and during halothane (1.2%), enflurane (2.5%), and isoflurane anesthesia (1.6%), verapamil was infused for 30 min in doses calculated to obtain similar plasma concentrations (83 +/- 10, 82 +/- 6, 81 +/- 10, and 77 +/- 9 ng.ml-1, respectively).",Cardiovascular effects of and interaction between calcium blocking drugs and anesthetics in chronically instrumented dogs. V. Role of pharmacokinetics and the autonomic nervous system in the interactions between verapamil and inhalational anesthetics. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2888422/),,83,215807,DB00228,Enflurane
,2888422,plasma concentrations,"In a first group of seven dogs, studied awake and during halothane (1.2%), enflurane (2.5%), and isoflurane anesthesia (1.6%), verapamil was infused for 30 min in doses calculated to obtain similar plasma concentrations (83 +/- 10, 82 +/- 6, 81 +/- 10, and 77 +/- 9 ng.ml-1, respectively).",Cardiovascular effects of and interaction between calcium blocking drugs and anesthetics in chronically instrumented dogs. V. Role of pharmacokinetics and the autonomic nervous system in the interactions between verapamil and inhalational anesthetics. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2888422/),,82,215808,DB00228,Enflurane
,2888422,plasma concentrations,"In a first group of seven dogs, studied awake and during halothane (1.2%), enflurane (2.5%), and isoflurane anesthesia (1.6%), verapamil was infused for 30 min in doses calculated to obtain similar plasma concentrations (83 +/- 10, 82 +/- 6, 81 +/- 10, and 77 +/- 9 ng.ml-1, respectively).",Cardiovascular effects of and interaction between calcium blocking drugs and anesthetics in chronically instrumented dogs. V. Role of pharmacokinetics and the autonomic nervous system in the interactions between verapamil and inhalational anesthetics. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2888422/),,81,215809,DB00228,Enflurane
,2888422,plasma concentrations,"In a first group of seven dogs, studied awake and during halothane (1.2%), enflurane (2.5%), and isoflurane anesthesia (1.6%), verapamil was infused for 30 min in doses calculated to obtain similar plasma concentrations (83 +/- 10, 82 +/- 6, 81 +/- 10, and 77 +/- 9 ng.ml-1, respectively).",Cardiovascular effects of and interaction between calcium blocking drugs and anesthetics in chronically instrumented dogs. V. Role of pharmacokinetics and the autonomic nervous system in the interactions between verapamil and inhalational anesthetics. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2888422/),,77,215810,DB00228,Enflurane
,2888422,heart rate,"In awake dogs, verapamil induced an increase in heart rate (24 +/- 5 bpm) and PR interval (35 +/- 9 msec) and a decrease in mean arterial pressure (-5 +/- 2 mmHg) and dP/dt (-494 +/- 116 mmHg/s).",Cardiovascular effects of and interaction between calcium blocking drugs and anesthetics in chronically instrumented dogs. V. Role of pharmacokinetics and the autonomic nervous system in the interactions between verapamil and inhalational anesthetics. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2888422/),bpm,24,215811,DB00228,Enflurane
,7283113,half-life,"While duration and half-life of the alpha-phase are prolonged, the half-life of the beta-phase (150 min) remains almost unchanged.",[Prevention of fentanyl rebound by administration of cimetidine (author's transl)]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7283113/),min,150,216975,DB00228,Enflurane
,3752571,terminal volume of distribution at steady-state,"Verapamil terminal volume of distribution at steady-state was reduced by halothane, enflurane, and isoflurane exposure as compared with awake: 65 +/- 10, 80 +/- 9, and 93 +/- 191, respectively, versus 132 +/- 121 (mean +/- SEM; P less than 0.05).",Effects of inhalational anesthetics on verapamil pharmacokinetics in dogs. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3752571/),,65,221707,DB00228,Enflurane
,3752571,terminal volume of distribution at steady-state,"Verapamil terminal volume of distribution at steady-state was reduced by halothane, enflurane, and isoflurane exposure as compared with awake: 65 +/- 10, 80 +/- 9, and 93 +/- 191, respectively, versus 132 +/- 121 (mean +/- SEM; P less than 0.05).",Effects of inhalational anesthetics on verapamil pharmacokinetics in dogs. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3752571/),,80,221708,DB00228,Enflurane
,3752571,terminal volume of distribution at steady-state,"Verapamil terminal volume of distribution at steady-state was reduced by halothane, enflurane, and isoflurane exposure as compared with awake: 65 +/- 10, 80 +/- 9, and 93 +/- 191, respectively, versus 132 +/- 121 (mean +/- SEM; P less than 0.05).",Effects of inhalational anesthetics on verapamil pharmacokinetics in dogs. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3752571/),,93,221709,DB00228,Enflurane
,3752571,terminal volume of distribution at steady-state,"Verapamil terminal volume of distribution at steady-state was reduced by halothane, enflurane, and isoflurane exposure as compared with awake: 65 +/- 10, 80 +/- 9, and 93 +/- 191, respectively, versus 132 +/- 121 (mean +/- SEM; P less than 0.05).",Effects of inhalational anesthetics on verapamil pharmacokinetics in dogs. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3752571/),,132,221710,DB00228,Enflurane
,3752571,total clearance,"Verapamil total clearance was also reduced by halothane, enflurane, and isoflurane as compared with awake: 37 +/- 4, 39 +/- 2 and 41 +/- 31 X h-1, respectively, versus 64 +/- 71 X h-1 (P less than 0.05).",Effects of inhalational anesthetics on verapamil pharmacokinetics in dogs. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3752571/),1/[h],37,221711,DB00228,Enflurane
,3752571,total clearance,"Verapamil total clearance was also reduced by halothane, enflurane, and isoflurane as compared with awake: 37 +/- 4, 39 +/- 2 and 41 +/- 31 X h-1, respectively, versus 64 +/- 71 X h-1 (P less than 0.05).",Effects of inhalational anesthetics on verapamil pharmacokinetics in dogs. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3752571/),1/[h],39,221712,DB00228,Enflurane
,3752571,total clearance,"Verapamil total clearance was also reduced by halothane, enflurane, and isoflurane as compared with awake: 37 +/- 4, 39 +/- 2 and 41 +/- 31 X h-1, respectively, versus 64 +/- 71 X h-1 (P less than 0.05).",Effects of inhalational anesthetics on verapamil pharmacokinetics in dogs. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3752571/),1/[h],41,221713,DB00228,Enflurane
,3752571,total clearance,"Verapamil total clearance was also reduced by halothane, enflurane, and isoflurane as compared with awake: 37 +/- 4, 39 +/- 2 and 41 +/- 31 X h-1, respectively, versus 64 +/- 71 X h-1 (P less than 0.05).",Effects of inhalational anesthetics on verapamil pharmacokinetics in dogs. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3752571/),1/[h],64,221714,DB00228,Enflurane
,3752571,cardiac output,Verapamil administered to awake animals resulted in a decrease from baseline in mean arterial pressure; 95 +/- 8 mmHg versus 108 +/- 4 mmHg (P less than 0.05): and an increase in cardiac output; 2.60 +/- 0.33 1 X min-1 versus 1.93 +/- 0.22 1 X min-1 (P less than 0.05).,Effects of inhalational anesthetics on verapamil pharmacokinetics in dogs. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3752571/),[1] / [min],2.60,221715,DB00228,Enflurane
,3752571,cardiac output,Verapamil administered to awake animals resulted in a decrease from baseline in mean arterial pressure; 95 +/- 8 mmHg versus 108 +/- 4 mmHg (P less than 0.05): and an increase in cardiac output; 2.60 +/- 0.33 1 X min-1 versus 1.93 +/- 0.22 1 X min-1 (P less than 0.05).,Effects of inhalational anesthetics on verapamil pharmacokinetics in dogs. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3752571/),[1] / [min],1.93,221716,DB00228,Enflurane
,8447208,elimination half-life,"The overall mean elimination half-life was 182 min, Vdss 169 l and the plasma clearance 910 ml min-1.",Pharmacokinetics of sufentanil in general surgical patients under different conditions of anaesthesia. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8447208/),min,182,240009,DB00228,Enflurane
,8447208,Vdss,"The overall mean elimination half-life was 182 min, Vdss 169 l and the plasma clearance 910 ml min-1.",Pharmacokinetics of sufentanil in general surgical patients under different conditions of anaesthesia. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8447208/),l,169,240010,DB00228,Enflurane
,8447208,plasma clearance,"The overall mean elimination half-life was 182 min, Vdss 169 l and the plasma clearance 910 ml min-1.",Pharmacokinetics of sufentanil in general surgical patients under different conditions of anaesthesia. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8447208/),[ml] / [min],910,240011,DB00228,Enflurane
,14975208,effect-site concentration,The target effect-site concentration was set at 3 microg/ml and the infusion was lasted for 15 minutes.,Concentrations of propofol in cerebral spinal fluid: target-controlled infusion. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14975208/),[μg] / [ml],3,246764,DB00228,Enflurane
,2013837,KET,kg-1.min-1 for 5 hr accompanied by an initial loading dose (26 mg/kg administered over 20 min) designed to produce a stable KET of 20 micrograms/ml of plasma.,The pharmacokinetics and pharmacodynamics of ketamine in dogs anesthetized with enflurane. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2013837/),[μg] / [ml],20,250399,DB00228,Enflurane
,2013837,t1/2 beta,Group 2: t1/2 beta = 122 +/- 9 vs.,The pharmacokinetics and pharmacodynamics of ketamine in dogs anesthetized with enflurane. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2013837/),,122,250400,DB00228,Enflurane
,2013837,CL,141 +/- 40 min (mean +/- SD) and CL = 18.1 +/- 5.9 vs.,The pharmacokinetics and pharmacodynamics of ketamine in dogs anesthetized with enflurane. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2013837/),,18.1,250401,DB00228,Enflurane
,2013837,KET,"When administered as a continuous infusion (Group 2), KET remained relatively stable at 22.1 +/- 4.6 micrograms/ml for 5 hr.",The pharmacokinetics and pharmacodynamics of ketamine in dogs anesthetized with enflurane. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2013837/),[μg] / [ml],22.1,250402,DB00228,Enflurane
,9489593,CLpv,"CLpv was significantly decreased from 26.4 +/- 13.2 ml kg(-1) min(-1) before anaesthesia, to 19.5 +/- 7.0 (P < 0.05) and 12.7 +/- 5.3 (P < 0.01) ml kg(-1) min(-1), respectively, during anaesthesia and after partial hepatectomy; These values were 72.1% (P < 0.01) and 48.5% (P < 0.01) of that observed at percutaneous transhepatic portography (PTP).",Clinical aspects of indocyanine green pharmacokinetics following portal vein administration. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9489593/),[ml] / [kg·min],26.4,254893,DB00228,Enflurane
,9489593,CLpv,"CLpv was significantly decreased from 26.4 +/- 13.2 ml kg(-1) min(-1) before anaesthesia, to 19.5 +/- 7.0 (P < 0.05) and 12.7 +/- 5.3 (P < 0.01) ml kg(-1) min(-1), respectively, during anaesthesia and after partial hepatectomy; These values were 72.1% (P < 0.01) and 48.5% (P < 0.01) of that observed at percutaneous transhepatic portography (PTP).",Clinical aspects of indocyanine green pharmacokinetics following portal vein administration. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9489593/),[ml] / [kg·min],19.5,254894,DB00228,Enflurane
,9489593,CLpv,"CLpv was significantly decreased from 26.4 +/- 13.2 ml kg(-1) min(-1) before anaesthesia, to 19.5 +/- 7.0 (P < 0.05) and 12.7 +/- 5.3 (P < 0.01) ml kg(-1) min(-1), respectively, during anaesthesia and after partial hepatectomy; These values were 72.1% (P < 0.01) and 48.5% (P < 0.01) of that observed at percutaneous transhepatic portography (PTP).",Clinical aspects of indocyanine green pharmacokinetics following portal vein administration. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9489593/),[ml] / [kg·min],12.7,254895,DB00228,Enflurane
,9489593,CLiv,"CLiv was significantly decreased from 14.6 +/- 5.3 ml kg(-1) min(-1) before anaesthesia, to 9.4 +/- 3.6 (P < 0.05) and 9.8 +/- 4.1 (P < 0.05) ml kg(-1) min(-1), respectively, after partial hepatectomy and 12 h after operation; These values were 68.9% (P < 0.05) and 73.5% (P < 0.05) of the value at PTP.",Clinical aspects of indocyanine green pharmacokinetics following portal vein administration. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9489593/),[ml] / [kg·min],14.6,254896,DB00228,Enflurane
,9489593,CLiv,"CLiv was significantly decreased from 14.6 +/- 5.3 ml kg(-1) min(-1) before anaesthesia, to 9.4 +/- 3.6 (P < 0.05) and 9.8 +/- 4.1 (P < 0.05) ml kg(-1) min(-1), respectively, after partial hepatectomy and 12 h after operation; These values were 68.9% (P < 0.05) and 73.5% (P < 0.05) of the value at PTP.",Clinical aspects of indocyanine green pharmacokinetics following portal vein administration. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9489593/),[ml] / [kg·min],9.4,254897,DB00228,Enflurane
,9489593,CLiv,"CLiv was significantly decreased from 14.6 +/- 5.3 ml kg(-1) min(-1) before anaesthesia, to 9.4 +/- 3.6 (P < 0.05) and 9.8 +/- 4.1 (P < 0.05) ml kg(-1) min(-1), respectively, after partial hepatectomy and 12 h after operation; These values were 68.9% (P < 0.05) and 73.5% (P < 0.05) of the value at PTP.",Clinical aspects of indocyanine green pharmacokinetics following portal vein administration. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9489593/),[ml] / [kg·min],9.8,254898,DB00228,Enflurane
